Interleukin-6 blocking agents for treating COVID-19: a living systematic review
COVID-19 치료를 위한 인터루킨-6 차단제: 살아있는 체계적인 검토
Meta-Analysis
[키워드] 95% CI
adverse event
adverse events
age
all-cause mortality
anti-IL6
approach
articles
available data
average
baseline
benefit
Bia
blocking agent
blocking agents
Brazil
can not
Care
certainty
certainty of evidence
China
clinical
Clinical improvement
Cochrane COVID-19 Study Register
collected data
conducted
coronavirus disease
Coronavirus disease 2019
COVID-19
Critical
Critical disease
Data collection
death
defined
disease
disease severity
Efficacy and safety
eight
evaluate
evaluated
Evidence
excluded
FIVE
Follow-up
France
Health Organization
heterogeneity
hospital discharge
identify
IL-6
IL-6 blocking
Immune system dysfunction
immunosuppressive
incidence
Inclusion
individual
individual patient data meta-analyses
Inflammation
interleukin
interleukin 6
interleukin 6 (IL-6
Intubated
intubated patient
intubated patients
Italy
male
mechanical ventilation
Meta-analysis
methodology
Mild
moderate
Mortality
multicentre
nine
no increase
not intubated
organ support
Other outcomes
outcome
outcomes
oxygen
participant
Participants
Patient
patient data
patients with COVID-19
peer-reviewed
people with COVID-19
Placebo
platform
Platform trial
progression
proportion
protocol
randomised
randomised controlled trial
Randomised controlled trials
ranged
RCT
RCTs
reduce
Registered
registry
reported
risk of bia
Safety
sarilumab
score
searched
Selection
Serious Adverse Event
Serious Adverse Events
Seven
severe coronavirus disease
severity
siltuximab
standard care
Standard of care
subgroups of patient
systematic review
Tocilizumab
Tolerance
Treatment
Trial
trial participant
trial participants
trials
unlikely
USA
WHO
World Health Organization
[DOI] 10.1002/14651858.CD013881 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1002/14651858.CD013881 PMC 바로가기 [Article Type] Meta-Analysis